首页> 外文期刊>Molecular cancer research: MCR >The HER2- and heregulin b1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression
【24h】

The HER2- and heregulin b1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression

机译:HER2和heregulin b1(HRG)诱导的TNFR超家族成员Fn14促进HRG驱动的乳腺癌细胞迁移,侵袭和MMP9表达

获取原文
获取原文并翻译 | 示例
           

摘要

HER2 overexpression occurs in 15% to 20% of all breast cancers and is associated with increased metastatic potential and poor patient survival. Abnormal HER2 activation, either through HER2 overexpression or heregulin (HRG):HER3 binding, elicits the formation of potent HER2-HER3 heterodimers and drives breast cancer cell growth and metastasis. In a previous study, we found that fibroblast growth factor-inducible 14 (Fn14), a member of the TNF receptor superfamily, was frequently overexpressed in human HER2+ breast tumors. We report here that HER2 and Fn14 are also coexpressed in mammary tumors that develop in two different transgenic mouse models of breast cancer. In consideration of these findings, we investigated whether HER2 activation in breast cancer cells could directly induce Fn14 gene expression. We found that transient or stable transfection of MCF7 cells with a HER2 expression plasmid increased Fn14 protein levels. Also, HRG1-β1 treatment of MCF7 cells transiently induced Fn14 mRNA and protein expression. Both the HER2- and HRG1-β1-induced increase in Fn14 expression in MCF7 cells as well as basal Fn14 expression in HER2 gene-amplified AU565 cells could be reduced by HER2 kinase inhibition with lapatinib or combined HER2 and HER3 depletion using siRNA. We also report that Fn14-depleted, HER2-overexpressing MCF7 cells have reduced basal cell migration capacity and reduced HRG1-β1-stimulated cell migration, invasion, and matrix metalloproteinase (MMP)-9 expression. Together, these results indicate that Fn14 may be an important downstream regulator of HER2/HER3-driven breast cancer cell migration and invasion.
机译:HER2过表达发生在所有乳腺癌的15%至20%中,并与转移潜能增加和患者生存不良有关。异常的HER2激活(通过HER2过表达或heregulin(HRG):HER3结合)引起有效的HER2-HER3异二聚体形成,并驱动乳腺癌细胞的生长和转移。在先前的研究中,我们发现,成纤维细胞生长因子诱导型14(Fn14)是TNF受体超家族的成员,在人HER2 +乳腺肿瘤中经常过表达。我们在这里报告,HER2和Fn14在乳腺癌的两种不同的转基因小鼠模型中发展的乳腺肿瘤中也共表达。考虑到这些发现,我们调查了乳腺癌细胞中的HER2激活是否可以直接诱导Fn14基因表达。我们发现用HER2表达质粒瞬时或稳定转染MCF7细胞增加了Fn14蛋白水平。同样,HRG1-β1处理MCF7细胞可瞬时诱导Fn14 mRNA和蛋白质表达。拉帕替尼可抑制HER2激酶或使用siRNA联合HER2和HER3耗竭,可降低HER2和HRG1-β1诱导的MCF7细胞中Fn14表达增加以及HER2基因扩增的AU565细胞中基础Fn14表达。我们还报告说,Fn14耗尽,HER2过表达的MCF7细胞具有减少的基础细胞迁移能力和减少的HRG1-β1刺激的细胞迁移,侵袭和基质金属蛋白酶(MMP)-9表达。总之,这些结果表明Fn14可能是HER2 / HER3驱动的乳腺癌细胞迁移和侵袭的重要下游调控因子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号